Thyroid Eye Disease (H05.83)
Thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy, is a complex autoimmune inflammatory disorder of the orbit that most commonly occurs in association with autoimmune thyroid disease, particularly Graves' disease. The condition arises when autoreactive immune cells target orbital fibroblasts expressing the thyroid-stimulating hormone receptor (TSHR) and, in many patients, the insulin-like growth factor-1 receptor (IGF-1R). Activation of these pathways drives inflammation, adipogenesis, and excessive production of glycosaminoglycans, leading to expansion of orbital fat and extraocular muscles. Clinically, TED manifests with proptosis, eyelid retraction, diplopia, ocular discomfort, and, in severe cases, compressive optic neuropathy that threatens vision. Disease progression typically involves an active inflammatory phase followed by a chronic fibrotic phase, underscoring the importance of timely diagnosis and intervention. Historically managed with corticosteroids, radiation therapy, and surgical rehabilitation, TED treatment has evolved significantly with the development of targeted biologic therapies. In particular, inhibition of IGF-1R with the monoclonal antibody teprotumumab has transformed the therapeutic landscape by addressing underlying disease mechanisms rather than simply suppressing inflammation. Continued advances in understanding the molecular and immunologic drivers of TED are expected to further refine precision therapeutic strategies and improve visual and quality-of-life outcomes for affected patients.
Causes
Thyroid eye disease (TED) is an autoimmune disorder most commonly associated with Graves' disease in which the immune system mistakenly targets tissues within the orbit. Autoreactive T and B lymphocytes generate antibodies against the thyroid-stimulating hormone receptor (TSHR), which is expressed not only on thyroid cells but also on orbital fibroblasts. Binding of these thyroid-stimulating antibodies activates TSHR and interacts with the insulin-like growth factor-1 receptor (IGF-1R), triggering inflammatory signaling, cytokine release, hyaluronan production, adipogenesis, and expansion of extraocular muscles and orbital fat. Genetic susceptibility, environmental factors such as smoking, and thyroid dysfunction further contribute to disease development and severity.
Pathophysiology
Thyroid eye disease is characterized by autoimmune-mediated inflammation and remodeling of the orbital tissues. The disease begins when autoreactive T cells and B cells target the thyroid-stimulating hormone receptor (TSHR) expressed on orbital fibroblasts and fibrocytes. B cells produce thyroid-stimulating antibodies that activate TSHR, while signaling through the insulin-like growth factor-1 receptor (IGF-1R) further amplifies the response. Activated immune cells release proinflammatory cytokines, including interferon-γ, tumor necrosis factor-α, interleukin-1β, and interleukin-6, which recruit additional inflammatory cells and perpetuate orbital inflammation. Orbital fibroblasts respond by producing large amounts of hyaluronan, a hydrophilic glycosaminoglycan that draws water into the tissues, causing edema and enlargement of the extraocular muscles and orbital fat. These fibroblasts may also differentiate into adipocytes and myofibroblasts, leading to fat expansion and fibrosis. The resulting increase in orbital tissue volume within the confined bony orbit produces the characteristic clinical manifestations of TED, including proptosis, eyelid retraction, diplopia, exposure keratopathy, and, in severe cases, compressive optic neuropathy.
Clinical features
Thyroid eye disease presents with a spectrum of ocular and periocular manifestations resulting from inflammation, expansion of orbital tissues, and fibrosis. Early symptoms commonly include ocular irritation, dryness, tearing, photophobia, retro-orbital pain, and a sensation of grittiness or pressure behind the eyes. Characteristic signs include eyelid retraction, periorbital edema, conjunctival injection, and proptosis (exophthalmos) due to expansion of orbital fat and extraocular muscles. Involvement of the extraocular muscles may lead to restrictive strabismus and diplopia, particularly in upward or lateral gaze. As the disease progresses, exposure keratopathy may develop from incomplete eyelid closure, increasing the risk of corneal ulceration. In severe cases, enlargement of orbital tissues can compress the optic nerve at the orbital apex, resulting in compressive optic neuropathy, characterized by decreased visual acuity, impaired color vision, visual field defects, and potentially permanent vision loss if not promptly treated. The disease typically evolves through an active inflammatory phase followed by a chronic fibrotic phase, with varying degrees of residual functional and cosmetic impairment.
Diagnosis
The diagnosis of thyroid eye disease is primarily clinical and is based on the presence of characteristic ocular findings in a patient with current or past autoimmune thyroid disease, most commonly Graves' disease. A comprehensive ophthalmologic examination should assess visual acuity, color vision, pupillary responses, eyelid position, degree of proptosis, ocular motility, and evidence of corneal exposure or optic nerve dysfunction. Laboratory evaluation typically includes thyroid function tests (TSH, free T4, and free T3) and measurement of thyroid autoantibodies, particularly thyroid-stimulating immunoglobulins (TSI) or TSH receptor antibodies (TRAb). Orbital imaging with computed tomography (CT) or magnetic resonance imaging (MRI) can demonstrate enlargement of the extraocular muscles, expansion of orbital fat, and apical crowding, while helping exclude alternative orbital disorders. Disease activity and severity are commonly assessed using standardized tools such as the Clinical Activity Score (CAS) and severity classification systems to guide treatment decisions. Prompt recognition of signs suggestive of compressive optic neuropathy—including decreased visual acuity, impaired color vision, relative afferent pupillary defect, or visual field loss—is critical, as these findings require urgent intervention to prevent permanent vision loss.
Mechanism of action videos
Therapeutic area: Immunology